Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • Boehringer Ingelheim Page 14 of 14 Trajenta Linagliptin, 5 MG Film Coated Tablet Response Document

    Загружено:

    hendranuramin
    1 просмотров1 страница
    This document summarizes clinical trial findings for the diabetes drug Trajenta (linagliptin). When used as an add-on to insulin treatment, linagliptin was found to be well-tolerated with side effects consistent with its known safety profile as a monotherapy or when used with other oral diabetes drugs. Constipation was identified as a potential additional side effect when used with insulin. The document is proprietary and confidential information from Boehringer Ingelheim regarding linagliptin.

    Исходное описание:

    tdumjfhvmn gufykgjb,nvcghfyigulhk,nm duyfvkhm nugubkjm nhvjj ihubjtufkygkbj

    Оригинальное название

    img46

    Авторское право

    © © All Rights Reserved

    Доступные форматы

    DOCX, PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ
    This document summarizes clinical trial findings for the diabetes drug Trajenta (linagliptin). When used as an add-on to insulin treatment, linagliptin was found to be well-tolerated with side effects consistent with its known safety profile as a monotherapy or when used with other oral diabetes drugs. Constipation was identified as a potential additional side effect when used with insulin. The document is proprietary and confidential information from Boehringer Ingelheim regarding linagliptin.

    Авторское право:

    © All Rights Reserved
    Скачайте в формате DOCX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    1 просмотров1 страница

    Boehringer Ingelheim Page 14 of 14 Trajenta Linagliptin, 5 MG Film Coated Tablet Response Document

    Загружено:

    hendranuramin
    This document summarizes clinical trial findings for the diabetes drug Trajenta (linagliptin). When used as an add-on to insulin treatment, linagliptin was found to be well-tolerated with side effects consistent with its known safety profile as a monotherapy or when used with other oral diabetes drugs. Constipation was identified as a potential additional side effect when used with insulin. The document is proprietary and confidential information from Boehringer Ingelheim regarding linagliptin.

    Авторское право:

    © All Rights Reserved
    Скачайте в формате DOCX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 1

    Boehringer Ingelheim Page 14 of 14

    Trajenta
    Linagliptin, 5 mg film coated tablet

    Response Document
    Proprietary confidential information © 2017 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

    antidiabetics. The potential side effects identified for linagliptin with insulin confirm prior
    findings for linagliptin (nasopharyngitis, cough, hypersensitivity and pancreatitis) when used
    as monotherapy or in combination with oral antidiabetics. Only constipation was identified as
    an additional potential side effect in patients with T2DM taking linagliptin as an add-on to
    insulin.

    REPONSE TO COMMENTS dated 23 June 2014

    Вам также может понравиться